Home › COPD
COPD clinical trials recruiting in the U.S.
98 studies for COPD are recruiting participants at sites across the United States.
COPD (chronic obstructive pulmonary disease) makes it hard for you to breathe. At first symptoms are mild, but they usually become more severe. Learn more.
Cities with the most studies
- Philadelphia, PA23 studies
- Miami, FL18 studies
- Birmingham, AL17 studies
- Boston, MA17 studies
- Houston, TX15 studies
- Orlando, FL15 studies
- Baltimore, MD14 studies
- Chicago, IL14 studies
- Dallas, TX12 studies
- Pittsburgh, PA12 studies
- New York City, NY11 studies
- Ann Arbor, MI10 studies
- Los Angeles, CA9 studies
- Winston-Salem, NC9 studies
- Detroit, MI9 studies
- Charlotte, NC9 studies
- Phoenix, AZ9 studies
- Kansas City, KS9 studies
- Hialeah, FL8 studies
- Newport Beach, CA8 studies
- Columbus, OH8 studies
- Cleveland, OH8 studies
- Tampa, FL7 studies
- Nashville, TN7 studies
- Durham, NC7 studies
- Kendall, FL7 studies
- Denver, CO7 studies
- Milwaukee, WI7 studies
- Farmington Hills, MI6 studies
- West Palm Beach, FL6 studies
- Jacksonville, FL6 studies
- Indianapolis, IN6 studies
- Aurora, CO6 studies
- Las Vegas, NV5 studies
- Shreveport, LA5 studies
- St. Louis, MO5 studies
- El Paso, TX5 studies
- Baton Rouge, LA5 studies
- Savannah, GA5 studies
- Rapid City, SD5 studies
By state
- Alabama21 studies
- Arizona17 studies
- California26 studies
- Colorado15 studies
- Connecticut3 studies
- Florida28 studies
- Georgia12 studies
- Idaho4 studies
- Illinois19 studies
- Indiana10 studies
- Iowa6 studies
- Kansas12 studies
- Kentucky5 studies
- Louisiana9 studies
- Maine3 studies
- Maryland16 studies
- Massachusetts25 studies
- Michigan22 studies
- Minnesota11 studies
- Mississippi3 studies
- Missouri7 studies
- Montana3 studies
- Nebraska5 studies
- Nevada8 studies
- New Jersey7 studies
- New York19 studies
- North Carolina22 studies
- Ohio17 studies
- Oklahoma8 studies
- Oregon6 studies
- Pennsylvania33 studies
- South Carolina14 studies
- South Dakota6 studies
- Tennessee14 studies
- Texas25 studies
- Utah6 studies
- Vermont5 studies
- Virginia12 studies
- Washington6 studies
- West Virginia5 studies
- Wisconsin8 studies
Recently updated studies
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 2, 2026 · NCT06283966Evaluation of the Paramedic Evaluation for Acute COPD Exacerbation
Recruiting
Ages 40 and older · All sexes · Updated Oct 2, 2026 · NCT07072039Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Oct 1, 2026 · NCT07190222WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department
Recruiting
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07558265To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
RecruitingPhase 2
Ages 40 to 85 · All sexes · Updated Sep 30, 2026 · NCT07684820Mindful Steps 2.0: Promoting Physical Activity in Patients With COPD and HF
Recruiting
Ages 40 and older · All sexes · Updated Sep 29, 2026 · NCT05934565A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
RecruitingPhase 2
Ages 40 to 80 · All sexes · Updated Sep 25, 2026 · NCT07725939A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 25, 2026 · NCT07780656: Vascular Function in Health and Disease
RecruitingPhase 1Healthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT02966665A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
RecruitingPhase 2
Ages 40 to 75 · All sexes · Updated Sep 25, 2026 · NCT07759245Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 22, 2026 · NCT07190209A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
RecruitingPhase 4
Ages 40 to 85 · All sexes · Updated Sep 22, 2026 · NCT07053423A Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 21, 2026 · NCT07793409An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema
Recruiting
Ages 40 to 80 · All sexes · Updated Sep 17, 2026 · NCT06035120A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)
RecruitingPhase 2
Ages 40 to 80 · All sexes · Updated Sep 15, 2026 · NCT07646587Nebulizer Versus Handheld Maintenance Therapy for Patients With COPD
RecruitingPhase 4
Ages 60 and older · All sexes · Updated Sep 14, 2026 · NCT07816835A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 9, 2026 · NCT07780669A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 9, 2026 · NCT07082738Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 4, 2026 · NCT07059091A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 3, 2026 · NCT06878261A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
RecruitingPhase 3
Ages 40 to 80 · All sexes · Updated Sep 3, 2026 · NCT06883305A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06603246COPD Exacerbation Follow Up
RecruitingObservational study
Ages 40 and older · All sexes · Updated Sep 2, 2026 · NCT07118306The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry
RecruitingObservational study
Ages 40 and older · All sexes · Updated Sep 1, 2026 · NCT07612878A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease
RecruitingPhase 2/3
Ages 35 to 80 · All sexes · Updated Aug 31, 2026 · NCT07363694From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.